SCHEMBL9055698

SCHEMBL9055698

CCN(N)C#N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22750778 0.78
SCHEMBL4258347 0.67
SCHEMBL23893212 0.66
SCHEMBL444554 0.65
SCHEMBL632731 0.65
SCHEMBL18884434 0.63
SCHEMBL4215210 0.62
SCHEMBL5423678 0.62
Cyanamide SCHEMBL28089099 0.62 ALDH1A1 (0.35)
Hydrochloric Acid SCHEMBL11396954 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107075498-A Selective advantage in fermentation 诺沃吉公司 2017-08-18 CN claimed
US-20240276957-A1 METHODS OF TREATMENT WITH AMINOLEVULINIC ACID SYNTHASE 2 (ALAS2) MODULATORS AGIOS PHARMACEUTICALS, INC. 2024-08-22 US disclosed
CN-114174288-A Methods of treatment with aminolevulinic acid synthase 2(ALAS2) modulators 安吉奥斯医药品有限公司 2022-03-11 CN disclosed
WO-2020247819-A2 METHODS OF TREATMENT WITH AMINOLEVULINIC ACID SYNTHASE 2 (ALAS2) MODULATORS AGIOS PHARMACEUTICALS, INC. (US) 2020-12-10 WO disclosed
CN-109293551-A Method and composition relevant to granulocyte colony stimulating factor receptor 利亘制药公司 2019-02-01 CN disclosed
CN-107075498-A Selective advantage in fermentation 诺沃吉公司 2017-08-18 CN disclosed
CN-104039761-A Methods and compositions related to granulocyte colony stimulating factor receptor LIGAND PHARM INC 2014-09-10 CN disclosed
CN-102712625-B Nitrogen-containing heteroaryl derivatives HOFFMANN LA ROCHE 2014-04-09 CN disclosed
CN-103214460-A Chemical compounds SYNGENTA PARTICIPATIONS AG 2013-07-24 CN disclosed
CN-102753184-A Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases SANOFI AVENTIS 2012-10-24 CN disclosed
CN-1964984-A Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof SANOFI AVENTIS DEUTSCHLAND (DE) 2007-05-16 CN disclosed
CN-1914205-A Pyrazolo [3, 4-b ] pyridine compounds and their use as phosphodiesterase inhibitors GLAXO GROUP LTD (GB) 2007-02-14 CN disclosed
CN-1791611-A 17beta-hydroxysteroid dehydrogenase inhibitors. STERIX LTD (GB) 2006-06-21 CN disclosed
CN-1751042-A Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors GLAXO GROUP LTD (GB) 2006-03-22 CN disclosed
CN-1694882-A Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors GLAXO GROUP LTD (GB) 2005-11-09 CN disclosed
CN-1149085-C Inhibition of RAF kinase with substituted heterocyclic ureas 2004-05-12 CN disclosed
CN-1148346-C Hydrazine derivative - 2004-05-05 CN disclosed
CN-1309634-A Hydrazine derivs. HOFFMANN LA ROCHE (CH) 2001-08-22 CN disclosed
CN-1290164-A Inhibition of RAF kinase with substituted heterocyclic ureas BAYER AG (US) 2001-04-04 CN disclosed
WO-1996012706-A1 NOVEL ACID PYRAZOLE AND PYRAZOLONE DERIVATIVES FOR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS ROUSSEL UCLAF (FR) 1996-05-02 WO disclosed